776 related articles for article (PubMed ID: 20538672)
1. Improvement of migraine headaches after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism.
Wahl A; Praz F; Tai T; Findling O; Walpoth N; Nedeltchev K; Schwerzmann M; Windecker S; Mattle HP; Meier B
Heart; 2010 Jun; 96(12):967-73. PubMed ID: 20538672
[TBL] [Abstract][Full Text] [Related]
2. Percutaneous closure of patent foramen ovale for migraine headaches refractory to medical treatment.
Wahl A; Praz F; Findling O; Nedeltchev K; Schwerzmann M; Tai T; Windecker S; Mattle HP; Meier B
Catheter Cardiovasc Interv; 2009 Jul; 74(1):124-9. PubMed ID: 19180663
[TBL] [Abstract][Full Text] [Related]
3. Primary transcatheter patent foramen ovale closure is effective in improving migraine in patients with high-risk anatomic and functional characteristics for paradoxical embolism.
Rigatelli G; Dell'Avvocata F; Ronco F; Cardaioli P; Giordan M; Braggion G; Aggio S; Chinaglia M; Rigatelli G; Chen JP
JACC Cardiovasc Interv; 2010 Mar; 3(3):282-7. PubMed ID: 20298985
[TBL] [Abstract][Full Text] [Related]
4. Transcatheter patent foramen ovale closure is effective in reducing migraine independently from specific interatrial septum anatomy and closure devices design.
Rigatelli G; Cardaioli P; Dell'Avvocata F; Giordan M; Braggion G; Chinaglia M; Roncon L
Cardiovasc Revasc Med; 2010; 11(1):29-33. PubMed ID: 20129358
[TBL] [Abstract][Full Text] [Related]
5. Impact of Percutaneous Closure of Interatrial Shunts on Migraine Attacks: Single-Operator Series and Review of the Literature.
Manolis AS
Rev Recent Clin Trials; 2017; 12(2):129-138. PubMed ID: 28356032
[TBL] [Abstract][Full Text] [Related]
6. Long-term results after fluoroscopy-guided closure of patent foramen ovale for secondary prevention of paradoxical embolism.
Wahl A; Kunz M; Moschovitis A; Nageh T; Schwerzmann M; Seiler C; Mattle HP; Windecker S; Meier B
Heart; 2008 Mar; 94(3):336-41. PubMed ID: 17639093
[TBL] [Abstract][Full Text] [Related]
7. Second transcatheter closure for residual shunt following percutaneous closure of patent foramen ovale.
Susuri N; Obeid S; Ulmi M; Siontis GCM; Wahl A; Windecker S; Nietlispach F; Meier B; Praz F
EuroIntervention; 2017 Sep; 13(7):858-866. PubMed ID: 28437244
[TBL] [Abstract][Full Text] [Related]
8. Embolic implications of combined risk factors in patients with patent foramen ovale (the CARPE criteria): consideration for primary prevention closure?
Rigatelli G; Dell'Avvocata F; Giordan M; Braggion G; Aggio S; Chinaglia M; Roncon L; Cardaioli P; Chen JP
J Interv Cardiol; 2009 Aug; 22(4):398-403. PubMed ID: 19515082
[TBL] [Abstract][Full Text] [Related]
9. Long-term experience and outcomes with transcatheter closure of patent foramen ovale.
Inglessis I; Elmariah S; Rengifo-Moreno PA; Margey R; O'Callaghan C; Cruz-Gonzalez I; Baron S; Mehrotra P; Tan TC; Hung J; Demirjian ZN; Buonanno FS; Ning M; Silverman SB; Cubeddu RJ; Pomerantsev E; Schainfeld RM; Dec GW; Palacios IF
JACC Cardiovasc Interv; 2013 Nov; 6(11):1176-83. PubMed ID: 24262618
[TBL] [Abstract][Full Text] [Related]
10. Determinants and clinical significance of persistent residual shunting in patients with percutaneous patent foramen ovale closure devices.
Shafi NA; McKay RG; Kiernan FJ; Silverman IE; Ahlquist M; Silverman DI
Int J Cardiol; 2009 Nov; 137(3):314-6. PubMed ID: 19616327
[TBL] [Abstract][Full Text] [Related]
11. Late results after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism using the amplatzer PFO occluder without intraprocedural echocardiography: effect of device size.
Wahl A; Tai T; Praz F; Schwerzmann M; Seiler C; Nedeltchev K; Windecker S; Mattle HP; Meier B
JACC Cardiovasc Interv; 2009 Feb; 2(2):116-23. PubMed ID: 19463412
[TBL] [Abstract][Full Text] [Related]
12. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
[TBL] [Abstract][Full Text] [Related]
13. Frequency of migraine headache relief following patent foramen ovale "closure" despite residual right-to-left shunt.
Jesurum JT; Fuller CJ; Kim CJ; Krabill KA; Spencer MP; Olsen JV; Likosky WH; Reisman M
Am J Cardiol; 2008 Oct; 102(7):916-20. PubMed ID: 18805122
[TBL] [Abstract][Full Text] [Related]
14. Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism: procedural and follow-up results after implantation of the Amplatzer®-occluder device.
Fischer D; Haentjes J; Klein G; Schieffer B; Drexler H; Meyer GP; Schaefer A
J Interv Cardiol; 2011 Feb; 24(1):85-91. PubMed ID: 20735710
[TBL] [Abstract][Full Text] [Related]
15. Transcranial Doppler quantification of residual shunt after percutaneous patent foramen ovale closure. Comparison of two devices.
Sorensen SG; Aguilar H; McKnight WK; Thomas H; Muhlestein JB
J Interv Cardiol; 2010 Dec; 23(6):575-80. PubMed ID: 20796165
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up after PFO device closure: Outcomes and Complications in a Single-center Experience.
Taggart NW; Reeder GS; Lennon RJ; Slusser JP; Freund MA; Cabalka AK; Cetta F; Hagler DJ
Catheter Cardiovasc Interv; 2017 Jan; 89(1):124-133. PubMed ID: 27027873
[TBL] [Abstract][Full Text] [Related]
17. Effect of Residual Interatrial Shunt on Migraine Burden After Transcatheter Closure of Patent Foramen Ovale.
Ben-Assa E; Rengifo-Moreno P; Al-Bawardy R; Kolte D; Cigarroa R; Cruz-Gonzalez I; Sakhuja R; Elmariah S; Pomerantsev E; Vaina LM; Ning M; Buonanno FS; Hung JW; Inglessis I; Palacios IF
JACC Cardiovasc Interv; 2020 Feb; 13(3):293-302. PubMed ID: 32029246
[TBL] [Abstract][Full Text] [Related]
18. The Flatstent versus the conventional umbrella devices in the percutaneous closure of patent foramen ovale.
Aral M; Mullen M
Catheter Cardiovasc Interv; 2015 May; 85(6):1058-65. PubMed ID: 25413379
[TBL] [Abstract][Full Text] [Related]
19. Long term follow up after percutaneous closure of PFO in 357 patients with paradoxical embolism: Difference in occlusion systems and influence of atrial septum aneurysm.
von Bardeleben RS; Richter C; Otto J; Himmrich L; Schnabel R; Kampmann C; Rupprecht HJ; Marx J; Hommel G; Münzel T; Horstick G
Int J Cardiol; 2009 May; 134(1):33-41. PubMed ID: 18715659
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of randomized trials on percutaneous patent foramen ovale closure for prevention of migraine.
Elbadawi A; Barssoum K; Abuzaid AS; Rezq A; Biniwale N; Alotaki E; Mohamed AH; Vuyyala S; Ogunbayo GO; Saad M
Acta Cardiol; 2019 Apr; 74(2):124-129. PubMed ID: 29914296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
